N-ethyl-prolinamide | 55446-83-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-ethyl-prolinamide
• 英文别名: DL-Pro-NHEt；proline ethylamide；DL-prolin-ethylamide；DL-Prolin-aethylamid；N-ethylpyrrolidine-2-carboxamide
• CAS: 55446-83-8
• 化学式: C₇H₁₄N₂O
• 分子量: 142.201
• InChiKey: KACAMSDOZKVKNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-ethyl-prolinamide 以 二氯甲烷 为溶剂， 反应 0.46h， 生成 Piv-L-Pro-NHEt
  参考文献：
  名称：

  Hosten, N.; Antenuis, M.J.O, Bulletin des Societes Chimiques Belges, 1988, vol. 97, # 1, p. 48 - 50

  摘要：

  DOI：
• 作为产物：
  描述：

  苄氧羰基脯氨酰乙胺 在 sodium hydroxide 、 氢溴酸 作用下， 以 磷酸酐 、 氯仿 、 溶剂黄146 为溶剂， 生成 N-ethyl-prolinamide
  参考文献：
  名称：

  Alkylamides of carboxyalkanoyl peptides and method for preparation

  摘要：

  描述了一种制备新颖的羧基肽烷酰胺的方法，其化学式为##STR1##，其中R是1-5个碳原子的芳基或烷基基团，A是肽键结合的脯氨酸或丙氨酸残基，B是直链键或肽键结合的脯氨酸或丙氨酸残基，X是CH.dbd.CH基团或1-3个碳原子的亚甲基基团。所述化合物具有抑制弹性酶的能力。

  公开号：

  US04554100A1

文献信息

• [EN] ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS
  申请人：REDX PHARMA PLC

  公开号：WO2017046606A1

  公开（公告）日：2017-03-23

  This invention relates to antibacterial and antimycobacterial drug compounds of formula (I). It also relates to pharmaceutical formulations of antibacterial drug compounds of formula (I). It also relates to uses of the derivatives in treating bacterial infections and to methods of treating bacterial infections. The compounds are particularly useful for treating bacterial infections that have developed resistance to other drug compounds, e.g. resistant strains of S. aureus.

  本发明涉及公式（I）的抗菌和抗分枝杆菌药物化合物。它还涉及公式（I）的抗菌药物化合物的制药配方。它还涉及利用这些衍生物治疗细菌感染的用途以及治疗细菌感染的方法。这些化合物特别适用于治疗对其他药物化合物产生抗药性的细菌感染，例如金黄色葡萄球菌的耐药菌株。
• [EN] PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTEINE KINASE 2-INDOLINONE A SUBSTITUTION PYRROLE
  申请人：SUGEN INC

  公开号：WO2001060814A2

  公开（公告）日：2001-08-23

  The present invention relates to pyrrole substituted 2-indolinone compounds of formula (I): and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefor are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及式(I)的吡咯取代的2-吲哚酮化合物及其药学上可接受的盐，该化合物可以调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面有用。
• PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST
  申请人：Napolitano Elio

  公开号：US20090292129A1

  公开（公告）日：2009-11-26

  A process for resolving a compound in racemic form comprising the following steps is described: a) reacting a compound in racemic form with a resolving agent, b) forming a diastereoisomeric complex of the resolving agent and an enantiomer of interest, c) separating the enantiomer of interest from the obtained diastereoisomer, wherein such a process is characterized in that said resolving agent is a compound of Formula (I). A diastereoisomeric complex between the resolving agent of Formula (I) and the enantiomer of interest is also described. The process according to the invention allows acid and basic racemic mixtures to be separated.

  本发明提供了一种用于分离外消旋化合物的方法，包括以下步骤：a）将外消旋化合物与分离剂反应，b）形成分离剂和所需对映体的非对映异构体复合物，c）从所得的非对映异构体中分离所需对映体。其中，所述分离剂为式（I）的化合物。本发明还描述了分离剂式（I）与所需对映体之间的非对映异构体复合物。本发明所述方法可以分离酸性和碱性外消旋混合物。
• Pharmaceutically Active Diazepanes
  申请人：Oberhauser Berndt

  公开号：US20080300237A1

  公开（公告）日：2008-12-04

  Leukocyte Function-Associated Antigen One (LFA-1) is a cell adhesion molecule selectively expressed on leukocytes, and plays a major role in the activation and trafficking of T lymphocytes in the tissue at sites of inflammation. In the last decade a large body of preclinical data has accumulated to establish the importance of LFA-1 as a biological target, 10 particularly in chronic, T-cell driven inflammatory conditions. The present invention provides pharmaceutically active 1,4-diazepan-2-ones of formula I useful for the treatment of conditions related to LFA-1 activity.

  白细胞功能相关抗原一（LFA-1）是一种细胞黏附分子，选择性地表达在白细胞上，对于在炎症部位的组织中T淋巴细胞的激活和转移起着重要作用。在过去的十年中，大量的临床前数据已经积累，以确定LFA-1作为生物学靶点的重要性，特别是在慢性的、T细胞驱动的炎症情况下。本发明提供了公式I的药物活性1,4-二氮杂环己烷-2-酮，用于治疗与LFA-1活性相关的疾病。
• COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
  申请人：Charrier Jean-Damien

  公开号：US20120040020A1

  公开（公告）日：2012-02-16

  The present disclosure relates to pyrazine compounds of formula I: wherein L, n, R 1 , and R 2 are as described in the specification. These compounds are useful as inhibitors of ATR protein kinase. The disclosure also relates to pharmaceutically acceptable compositions comprising the compounds of the disclosure; methods of treating of various diseases, disorders, and conditions using the compounds of the disclosure; processes for preparing the compounds of the disclosure; intermediates for the preparation of the compounds of the disclosure; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.

  本公开涉及式I的吡嗪化合物：其中L、n、R1和R2如规范所述。这些化合物可用作ATR蛋白激酶的抑制剂。本公开还涉及包含本公开化合物的药学上可接受的组合物；使用本公开化合物治疗各种疾病、障碍和病况的方法；制备本公开化合物的过程；制备本公开化合物的中间体；以及在体外应用中使用这些化合物的方法，例如研究生物和病理现象中的激酶、这些激酶介导的细胞内信号传导途径的研究以及新的激酶抑制剂的比较评估。